NEW YORK, Nov. 5, 2014 /PRNewswire/ -- Analyst Brief by Small Cap Traders. -- ScripsAmerica, Inc. (OTCBB: SCRC) is a supplier of prescription, OTC and nutraceutical drugs incepted in 2008 in the US. The firm provides pharmaceutical products to a wide range of end users including retail pharmacies, hospitals, long-term care facilities, government, and home care agencies. After experiencing a significant drop in profit margins in 2013, the firm restructured and has been experiencing a tremendous growth in both revenue and profit since the beginning of 2014. Q2 2014, ScripsAmerica reported $3,700,721 in total net revenue in compared to $91,628 reported during the same period in 2013, marking an increase of $3,609,093 in quarterly revenue. Also, profit margin in Q2 is 87%, in compare with a loss in 2013, signaling a positive trend for the firm. This growth in margin contributed to its management of the specialty pharmacy business which generated significant sales in the first six months of 2014.
On October 28th, 2014, ScripsAmerica confirmed its presence at See ThruEquity Microcap Investor Conference on November 12th in New York City. This gives ScripsAmerica a lucrative opportunity to access more funding from the investment community.
Since the beginning of the year, ScripsAmerica has continuously formed collaborative agreements with multiple players in the industry through acquisitions and partnerships. These firms include United Apothecapy, RapiMed Manufacturer, and Jungle Jim. As for the agreement with Jungle Jim, not only does it provide ScripsAmerica additional revenue base but also access to process prescriptions in 12 new states across the country. Going forward, with the increase in the revenue and customer base, the company should focus on ensuring strict control on its inventory, while achieving minimum turnaround time.
For a more detailed research with analyst comments and recommendation on ScripsAmerica, please follow the link. There is no cost obligation required to view analyst brief:
http://bit.ly/-SCRC-AnalystBrief
Copy and paste to browser may be required.
About Small Cap Traders
Once you have read our reports written by financial analysts you will understand that we make every effort to provide informative equity research reports for interested parties. 3rd party financial analysts provide a straightforward assessment of the profiled company and have pledged to remain free of influence when writing research reports. They include stocks traded in the NYSE, NASDAQ, and OTCBB exchanges.
Forward-Looking Disclaimer
This report may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward- looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of mentioned company to be materially different from the statements made herein.
Compliance Procedure
Content is researched, written and reviewed on a best-effort basis by a 3rd party research analyst. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below. We do not engage in high frequency trading.
A full disclaimer can be found by viewing the analyst report.
If you wish to have a company covered in more detail by our team, or wish to learn more about our services, please contact us at [email protected]. For any urgent concerns or inquiries please contact us at [email protected].
Contact: [email protected]
SOURCE Small Cap Traders
Share this article